Danaher Corporation (NYSE:DHR) Shares Acquired by US Bancorp DE

Key Points

• US Bancorp DE has increased its holdings in Danaher Corporation by 8.7%, now owning approximately 599,838 shares valued at $122.97 million.
• Danaher reported earnings of $1.80 per share, exceeding analyst expectations and showing a 3.4% increase in revenue compared to the previous year.
• The company recently announced a quarterly dividend of $0.32, reflecting a 0.6% yield and a payout ratio of 27.23%.

US Bancorp DE increased its position in Danaher Corporation (NYSE:DHR - Free Report) by 8.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 599,838 shares of the conglomerate's stock after buying an additional 47,844 shares during the period. US Bancorp DE owned 0.08% of Danaher worth $122,967,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DHR. GAMMA Investing LLC lifted its position in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after buying an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after buying an additional 1,601,800 shares in the last quarter. Capital World Investors lifted its position in shares of Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock worth $1,460,215,000 after buying an additional 1,566,658 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after buying an additional 1,107,998 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Danaher in the fourth quarter worth about $242,837,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 0.0%

Shares of NYSE:DHR traded down $0.08 on Friday, reaching $197.08. The company had a trading volume of 5,736,543 shares, compared to its average volume of 4,375,955. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The firm's 50 day simple moving average is $197.49 and its 200-day simple moving average is $202.44. The firm has a market capitalization of $141.12 billion, a PE ratio of 41.93, a PEG ratio of 2.74 and a beta of 0.73. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period in the previous year, the business earned $1.72 EPS. The firm's revenue for the quarter was up 3.4% on a year-over-year basis. As a group, analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 25th. Investors of record on Friday, June 27th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher's dividend payout ratio (DPR) is 27.23%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of recent research reports. The Goldman Sachs Group decreased their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. Citigroup restated a "buy" rating on shares of Danaher in a research report on Monday, April 7th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Jefferies Financial Group decreased their price objective on Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Finally, Leerink Partners upped their price objective on Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a research report on Wednesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.